Covalon to Showcase ColActive® Brand of Advanced Bio-Matrix Dressings at the Symposium on Advanced Wound
Care
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:COV), an advanced medical technologies company, today announced
that it will be showcasing its advanced wound care line up of products at the Symposium on Advanced Wound Care Fall meeting (“SAWC
Fall”) in Las Vegas from the 7th to the 9th of October.
“Covalon has supported the efforts of the SAWC for years and we are proud to do so,” said Brian Pedlar, Chief Executive Officer
of Covalon. “Our position as an emerging leader in the advanced wound care space makes this an important springboard for the
following year of activity” Pedlar continued.
SAWC Fall serves as a forum to connect the entire wound care team — physicians, nurses, physical therapists, researchers,
scientists, podiatrists, and dietitians — with the foremost experts in wound care to improve patient outcomes through education. No
other wound care conference offers the level of education, advanced state-of-the-art clinical reviews and emerging research
findings.
In addition to exhibiting, Covalon’s ColActive® Transfer will be featured in a case study entitled: Assessment of a Novel
Biomatrix Wound Contact Layer in Conjunction with NPWT on an Abdominal Surgical Wound, which demonstrates its unique ability to
work under Negative Pressure Wound Therapy conditions.
Covalon offers unique, patent protected infection management and advanced wound management solutions for the wound clinician.
Covalon’s CovaWound™ and ColActive® brands when used together have the ability to rapidly promote wound closure and healing in both
acute and chronic wounds.
Visit the Covalon Technologies Ltd. booth #138 from October 7-9th at the Caesar’s Palace Convention Center in Las
Vegas.
About Covalon
Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the
world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies,
healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in
specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and
biocompatibility. To learn more about Covalon, visit our website at www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect the Company's current expectations regarding future
events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate",
"plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or
be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the
difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing
strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating
results and other risks, any of which could cause results, performance, or achievements to differ materially from the results
discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the
Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties
relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The
Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further
events or otherwise.
Web site: www.covalon.com
Twitter: @covalon
Covalon Technologies Ltd.
Brian Pedlar, 905.568.8400 x 233
CEO,
bpedlar@covalon.com
Toll free: 1.877.711.6055
View source version on businesswire.com: http://www.businesswire.com/news/home/20161007005439/en/